ArticleCancer management and research2025
Pan-Cancer Analysis of BST2 Expression, Prognostic Significance, and Immune Correlations.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the expression of the bone marrow stromal cell antigen 2 (BST2) gene in malignant tumors originating from various tissues and to explore its clinical significance. Methods: We employed the TCGA database, R software, GeneMANIA database, and biological information analysis technologies to analyze the expression of the BST2 gene across various tumor tissues at different pathological stages and to assess its association with tumor prognosis, mutations, immune invasion, immune checkpoint-related genes, and associated pathways. Validation was performed using skin cutaneous melanoma cell lines, including M14, A375, B16-F10, and A2058. Results: The expression of the BST2 gene varied across tumors of different origins, showing both increased and decreased levels. BST2 expression was closely associated with patient prognosis. In pan-kidney cohort, renal clear cell carcinoma, pancreatic cancer, and uterine sarcoma, its expression significantly differed across pathological stages. Additionally, in most tumors, BST2 expression correlated positively with immune infiltration and was linked to immune checkpoint-related genes. Validation of skin cutaneous melanoma cell lines displayed BST2 expression was significantly elevated in melanoma cell lines compared with the normal human melanocyte line. Conclusion: This pan-cancer analysis highlights the correlation between BST2 expression and tumor type, prognosis, pathological stage, tumor mutations, and immune invasion. The findings suggest that BST2 may serve as an effective prognostic biomarker with potential applications in clinical diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.